After coming up short in COVID, Valneva focuses on chikungunya vaccine launch

After striking out in an attempt to create a niche for its COVID-19 vaccine, Valneva is taking its swings at what it does best—developing, manufacturing and commercializing vaccines for a variety of infectious diseases with unmet needs.

Previously at the top of the French company’s priority list was advancing shots that can defend against Lyme disease and the Zika virus. And now, most importantly for Valneva, is the launch of its new vaccine for the chikungunya virus.